In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Kurzik Dumke, Ursula ^a   Hörner, Manuela ^a   Nicotra, Maria R ^b   Koslowski, Michael ^a   Natali, Pier G ^c,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b CNR   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR SUPPRESSOR PROTEIN; TUMOROUS IMAGINAL DISC PROTEIN; UNCLASSIFIED DRUG; DNAJA3 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 40; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; ANIMAL; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP40 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MAMMARY GLANDS, HUMAN; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2;

EID: 77953586242     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-58     Document Type: Article

References (34)

1. Yin X, Rozakis-Adcock M. Genomic organization and expression of the human tumorous imaginal disc (TID1) gene. Gene 2001, 278:201-210. 10.1016/S0378-1119(01)00720-X, 11707338.
2. Kurzik-Dumke U, Gundacker D, Rentrop M, Gateff E. Tumor suppression in Drosophila is causally related to the function of the lethal(2)tumorous imaginal discs gene, a dnaJ homolog. Dev Genetics 1995, 16:64-76.
3. Ohtsuka K, Hata M. Molecular chaperone function of mammalian Hsp70 and Hsp40- review. Int J Hyperthermia 2000, 16:231-2452. 10.1080/026567300285259, 10830586.
4. Qiu X-B, Shao Y-M, Miao S, Wang L. The diversity o the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 2006, 63:2560-2570. 10.1007/s00018-006-6192-6, 16952052.
5. Vos MJ, Hageman J, Carra S, Kampinga HH. Structural and functional diversities between members of the human HSPB, HSPH, HSPA and DNAJ chaperone families. Biochemistry 2008, 47:7001-7011. 10.1021/bi800639z, 18557634.
6. Canamasas I, Debes A, Natali PG, Kurzik-Dumke U. Understanding Human Cancer Using Drosophila: Tid47, a cytosolic product of the DnaJ-like tumor suppressor gene l(2)tid, is a novel molecular partner of Patched related to skin cancer. J Biol Chem 2003, 278:30952-30960. 10.1074/jbc.M304225200, 12783860.
7. Kurzik-Dumke U, Czaja J. Htid-1, the human homolog of the Drosophila melanogaster l(2)tid tumor suppressor, defines a novel physiological role of APC. Cellular Signaling 2007, 18:1973-1985.
8. Schilling B, De-Medina T, Syken J, Vidal M, Münger K. A novel human DnaJ protein, hTid- 1 homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillommavirus type 16 E7 oncoprotein. Virology 1998, 247:74-85. 10.1006/viro.1998.9220, 9683573.
9. Sarkar S, Pollack BP, Lin K-T, Kotenko SV, Cook JR, Lewis S, Pestka S. HTid-1, a human DnaJ protein, modulates the interferon signalling pathway. J Biol Chem 2001, 276:49034-49042. 10.1074/jbc.M103683200, 11679576.
10. Cheng H, Cenciarelli H, Shao Z, Vidal M, Parks WP, Pagano M, Cheng-Mayer C. Human T cell leukaemia virus type 1 Tax associates with a molecular chaperone complex containing hTid-1 and Hsp70. Current Biol 2001, 11:1771-1775.
11. Cheng H, Cenciarelli C, Tao M, Parks WP, Cheng-Mayer C. HTLV-1 Tax-associated hTid-1, a human DnaJ protein, is a repressor of IκB Kinase β subunit. J Biol Chem 2002, 277:20605-20610. 10.1074/jbc.M201204200, 11927590.
12. Bae M-K, Jeong J-W, Kim S-H, Kim S-Y, Kang YJ, Kim D-M, Bae S-K, Yun I, Trentin GA, Rozakis-Adcock M, Kim K-W. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1α. Cancer Res 2005, 65:2520-2525. 10.1158/0008-5472.CAN-03-2735, 15805242.
13. Kurzik-Dumke U, Hörner M, Czaja J, Nicotra MR, Simiantonaki N, Koslowski M, Natali PG. Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med 2008, 21:19-31.
14. Liu H-Y, MacDonald JIS, Hryciw T, Li C, Meakin SO. Human Tid1 associates with TRK receptor tyrosine kinases and regulates neurite outgrowth in NNR5-TRKA Cells. J Biol Chem 2005, 7:19461-19471.
15. Kim S-W, Chao T-H, Xiang R, Campbell MJ, Fearns C, Lee J-D. Tid1, the human homoloque of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells. Cancer Res 2004, 64:7732-7739. 10.1158/0008-5472.CAN-04-1323, 15520177.
16. Citri A, Yarden Y. EGF-ERBB signalling: towards the system level. Nature Rev Molec Cell Biol 2006, 7:7505-7516.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
18. Agus BD, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non small cell lung cancer, prostate cancer and ovarian cancer. Semin In Oncol 2000, 27:53-63.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
20. Sobin LH, Wittening CH. TNM Classification of Malignant Tumors 2002, J Willey-Liss, Willey Sons, Inc., New York.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow- up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
22. Sotiriou C, Pusztai L. Gene-expression signature in breast cancer. New Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
23. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini P-L. Combined allogenic tumor cell vaccination and systemic interleukin 12 prevent mammary carcinogenesis in HER- 2/neu transgenic mice. J Exp Med 2001, 194:1195-1206. 10.1084/jem.194.9.1195, 2195980, 11696586.
24. Wolf-Yadiin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim H-D, Grantcharova V, Lauffenburger DA, White FM. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-43. 10.1200/JCO.2006.09.2775, 17159189.
25. Edwards K, Munger K. Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple signalling. Oncogene 2004, 23:8419-8431. 10.1038/sj.onc.1207732, 15156195.
26. Kim S-W, Hayashi M, LO J-F, Fearns C, Xiang R, Lazennec G, Xang Y, Lee J-D. Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8. Cancer Res 2005, 65:8784-8791. 10.1158/0008-5472.CAN-04-4422, 16204048.
27. Earp HS, Calvo BF, Sartor CI. The EGF receptor family multiple roles in proliferation, differentiation, and neoplasia with an emphasis on Her-4. Trans Am Clin and Climatol Assoc 2003, 114:315-334.
28. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signalling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinoma. Oncogene 1995, 10:1813-182.
29. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655. 10.1093/emboj/16.7.1647, 1169769, 9130710.
30. Fiorini M, Alimandi M, Fiorentino L, Sala G, Segatto O. Negative regulation of receptor tyrosine kinase signal. FEBS Lett 2001, 490:132-141. 10.1016/S0014-5793(01)02116-0, 11223028.
31. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y. LRIG1 restricts growth factor signalling by enhancing receptor ubiquitynation and degradation. EMBO J 2004, 23:3270-3281. 10.1038/sj.emboj.7600342, 514515, 15282549.
32. Kario E, Marmor MD, Adamsky K, Amit I, Amariglio N, Rechavi G, Yarden Y. Suppressors of cytokine signalling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 2005, 280:7038-7048. 10.1074/jbc.M408575200, 15590694.
33. Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, Alema S, Benedetti P, Segatto O. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen- induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 2000, 20:7735-7750. 10.1128/MCB.20.20.7735-7750.2000, 86354, 11003669.
34. Anastasi S, Baietti MF, Frosi Y, Alemà S, Segatto O. The evolutionary conserved EBR module of RALT/MIG6, mediates suppression of the EGFR catalytic activity. Oncogene 2007, 26:78337849.